their prognosis. In all patients with ARVC, primary intervention focuses on the prevention of disease progression. Patients are discouraged from participation in vigorous exercise as arrhythmias and sudden death events frequently occur at or around the time of exercise. 17 Exercise additionally results in increased myocardial stress leading to the mechanical disruption of cell-cell junctions thus accelerating disease progression. 18 For these reasons, many patients with ARVC are also prophylactically treated with beta-blockers, although no trial has demonstrated a significant mortality benefit for this therapy. Screening family members of patients with ARVC for clinical or genetic evidence of disease is highly encouraged as up to 50 % of relatives will test positive for the disease. Importantly, electrographic changes commonly precede structural changes, thus screening with an electrocardiogram may be effective in identifying early stages of the disease. 19 In patients who develop symptoms, the mainstays of therapy have focused on antiarrhythmic medications, radiofrequency catheter ablation and the implantation of implantable cardioverter-defibrillators (ICDs).
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Risk Stratification and Therapeutic Options
Several retrospective studies have been conducted to identify highrisk features of the disease in order to guide therapy. Established high-risk features include significant RV dysfunction, left ventricular involvement, history of syncope and development of sustained VT. [20] [21] [22] Of the available treatment modalities, only ICDs have consistently been demonstrated to affect patient mortality. In one study, the survival benefit of ICD implantation was close to 25 % over a 4-year follow-up period. 23 A recent meta-analysis estimated the annual mortality rate of patients with ARVC who underwent ICD implantation at 0.9 %, substantially lower than those without ICDs. 24 For this reason, patients with high-risk features are recommended to undergo ICD implantation by the American College of Cardiology, American Heart Association and the European Society of Cardiology. 25 ICD therapy, however, does not decrease the rate of ventricular arrhythmias or disease progression. Additionally, ICD implantation carries a risk of procedural complications, tricuspid regurgitation and inappropriate therapy, which may contribute to patient morbidity. The annual rate of inappropriate therapy in those with ICDs has been estimated to be as high as 4 %. 24 Therefore, the concomitant utilisation of catheter ablation and antiarrhythmic therapy is often necessary with the goals of reducing arrhythmia recurrence, decreasing ICD therapy and improving patient symptoms.
Catheter ablation has historically been effective in terminating malignant arrhythmias in the short term, but rates of VT recurrence following endocardial ablation are reported to be as high as 50-75 % within 3 years due to the progressive nature of the disease. 26, 27 Recognition of the larger role played by the epicardial arrhythmogenic substrate in ARVC has led to an increased focus on combined endocardial and epicardial ablation approaches. In a recent study comparing endocardial to endo+epicardial ablation, 83 % of patients treated with the combined approach remained arrhythmia free at 3 years compared with 52 % of patients treated with only endocardial ablation. 27 Another study reported a similar success rate of 77 % with an endo+epicardial approach over an average follow-up of 18 months. 28 While the results are very promising, it is important to recognise that epicardial ablation carries a substantial risk of complications such as epicardial bleeding and coronary stenosis occurring in approximately 5 % of cases. 29 Nevertheless, catheter ablation remains an important therapeutic modality for decreasing patient morbidity in conjunction with ICD implantation and antiarrhythmic medication.
Antiarrhythmic Therapy
Individual Antiarrhythmic Therapy
Overall data on the use of antiarrhythmic agents in ARVC are relatively limited as no randomised clinical trials have been conducted to compare the efficacy of agents in this condition. Early studies investigating the use of antiarrhythmics in ARVC were small, focused on inhomogeneous patient cohorts with variable follow-up periods, and evaluated largely empirical medication choice. [30] [31] [32] [33] [34] The first study to systematically assess the efficacy of antiarrhythmic therapy in ARVC was published in 1992 by Wichter et al. 35 The initial study focused on 81 patients with proven or highly probable ARVC, but was later expanded to 191 patients in 2000. 36 All patients underwent electrophysiological study and were tested for the A total of 608 antiarrhythmic tests were conducted with various agents including beta-blockers, sodium channel blockers, verapamil, sotalol, amiodarone and combination therapy (see Figure 1) . Sotalol, administered at a dosage of 320-640 mg/day, was determined to be the most effective therapy with approximately 68 % of patients achieving complete or partial arrhythmia suppression. Other therapies were less effective with Class I agents and amiodarone demonstrating only an 18 % and 26 % efficacy, respectively. Beta-blockers and verapamil proved to be most effective in patients with non-inducible arrhythmias on electrophysiology study and in patients thought to have triggered activity as the underlying mechanism of arrhythmia. In these patients, efficacy for these agents was 25 % and 44 %, respectively.
Based upon these observations, several conclusions were reached by the authors. First, sotalol appeared to be the most effective antiarrhythmic agent in the treatment of ARVC-associated arrhythmias.
Second, amiodarone use should be limited given significant long-term toxicity and questionable efficacy. Lastly, patients with arrhythmias presumed to be brought on by triggered activity as opposed to re-entry may benefit from beta-blockers and verapamil. These conclusions were further tested in a report from the North American ARVC Registry published in 2009 by Marcus et al. 37 In this prospective cohort study, a group of 95 ARVC patients with implanted 
Combination Antiarrhythmic Therapy
In patients who demonstrate poor response to individual agents, therapy with multiple antiarrhythmic medications may be considered.
However, even fewer data exist to guide the selection of agents for use in combination therapy.
In the Wichter et al. study described above, a minority of patients were treated with combination therapy. 35 In their cohort, the combination of Class I agents with amiodarone and sotalol were effective in a small number of patients in whom individual drug therapy had failed.
Other reports indicate that the use of Class I agents combined with sotalol may be effective in controlling arrhythmias in those refractory to single agent therapy and failed endocardial ablation. 38, 39 One recent report demonstrated the effective addition of flecainide to patients receiving sotalol with resultant reduction in recurrent arrhythmias. VT control in all patients. 40 Only four patients in the study had documented ARVC, however. In another small study by Leclercq et al.
focused on ARVC patients, the combination of amiodarone and beta blockers was likewise shown to result in VT suppression in all patients treated. 39 It has been postulated that this combination is particularly effective due to the Class III and II action of the agents, which may work especially well in the catechomaline dependent arrhythmias in ARVC. This mechanism may also partially explain the efficacy of sotalol demonstrated in the Wichter et al. study.
Despite the promising results of several studies, much more research is necessary to establish the efficacy of combination therapy in treatment of ARVC. Additionally, toxicity of agents may increase when used in combination and thus such therapy should be used with caution. Nevertheless, in patients failing to achieve adequate arrhythmia control with an individual agent, combination therapy warrants consideration. 
